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ABSTRACT Little is known about the characteristics and treatments of patients with severe asthma
across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe
Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration
and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in
European severe asthma registries and treatments before starting biologicals.
This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma
registries that joined SHARP with established patient databases.
Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors.
Current smokers ranged from 0% (Poland and Sweden) to 9.5% (Belgium), mean body mass index ranged
from 26.2 (Italy) to 30.6 kg·m−2 (the UK) and the largest difference in mean pre-bronchodilator forced
expiratory volume in 1 s % predicted was 20.9% (the Netherlands versus Hungary). Before starting
biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged
from 700 to 1335 µg·day−1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-
5 antibody and from 772 to 1344 µg·day−1 in those starting anti-IgE (Slovenia versus Spain). Maintenance
oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to
56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively.
The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics
and treatment, often appearing not to comply with the current European Respiratory Society/American
Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals
were different from inclusion criteria in clinical trials and varied between countries.
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The European Respiratory Society (ERS) Severe Heterogeneous Asthma Research collaboration,
Patient-centred (SHARP) Clinical Research Collaboration (CRC) was set up in 2018 to harmonise severe
asthma management across Europe and unravel underlying heterogeneity in a patient-centred way [1]. The
current project involves the first structured assessment and comparison of national severe asthma registries
that are part of SHARP to discover strengths/weaknesses in those registries and to evaluate severe asthma
and its treatment across Europe.
Significant progress has been made in the field of severe asthma since the turn of the millennium [2]. In
particular, the introduction of novel biologicals for patients with severe asthma has provided new effective
options for medical treatment, beginning with the anti-IgE monoclonal antibody, omalizumab, and more
recently anti-interleukin (IL)-5 antibodies, mepolizumab, reslizumab and benralizumab. The use of these
biologicals is often restricted to patients who fulfil the definition of severe asthma according to ERS/
American Thoracic Society (ATS) guidelines in whom all potential aggravating factors have been
eliminated and pre-specified criteria fulfilled, such as high-dose inhaled corticosteroid (ICS)/long-acting
β-agonist (LABA) treatment, multiple exacerbations in the previous year and/or chronic use of oral
corticosteroids (OCSs) [3].
The most recent Global Initiative for Asthma difficult-to-treat and severe asthma guide introduces a new
approach to the management of asthma [4], better reflecting the recommendations of The Lancet
Commission on asthma [5, 6] that highlighted the need for a multidimensional assessment and the
introduction of treatable mechanisms in asthma management. However, the definition of severe asthma is
still not unambiguous and it has been suggested that an improved definition, including risk assessment
and a better reflection of clinical reality, should be established. Asthma death is arguably the most severe
outcome, but most deaths occur in patients with nonsevere asthma with low levels of treatment [7]. Many
disease aggravating factors, both patient related (e.g. psychological factors, comorbidities) and
environmental (airborne allergens and air pollution), socioeconomic factors (housing and health
insurance) and healthcare accessibility factors are difficult or impossible to eliminate. Furthermore, the
expertise of the treating physician and the facilities of the treatment centre are likely to influence levels of
asthma control. Finally, the choices of treatment (including starting biologicals) are effected by differences
in healthcare systems, reimbursement policies and accessibility to medication.
In the present study, we explored the prevalence as well as the characteristics of patients with “severe
asthma” reported by physicians, which are likely to differ depending on the region, climate, healthcare
system and expertise of the treatment team. Furthermore, we explored the severity of disease (using the
treatment of the patient and biomarkers as a proxy) of severe asthma patients before starting biologicals,
also expecting differences between European countries. We compared the characteristics of those patients
who started with high-cost therapies (biologicals, bronchial thermoplasty and high-altitude revalidation)
within these registries and stratified the patient cohort for the two most commonly used groups of
biologicals (anti-IL-5 and anti-IgE). This study showed the need for harmonisation across registries and
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guidelines, and the requirement to collect the same set of minimal clinical data across cohorts which will
enable better coordination of treatment efforts using biologicals across Europe.
Materials and methods
Study subjects
Data from 11 different European national registries for severe asthma were eligible for inclusion in the
analysis (figure 1). There were no general inclusion criteria provided for the patients in these registries, so
these differed between registries (figure 2). Most European registries included patients who fulfilled the
severe asthma criteria according to the joint ERS/ATS guidelines [3], but in some cases national asthma
guidelines were used or all patients who attended specialist asthma centres were qualified for inclusion.
Four registries focused enrolment into registries of patients that were either in the process of being
considered for or were starting treatment with biologicals. One registry selected only patients with a
smoking history <5 pack-years and one registry included all patients who attended specialist referral
centres for severe asthma.
Study design
This study was a cross-sectional, retrospective analysis of aggregated registry data. In view of the
restrictions imposed on data confidentiality before and, in some cases, after imposition in the European
Union of the General Data Protection Regulation, data were received from individual national registries in
aggregate form composed of counts (percentages), mean with standard deviation and median
(interquartile range (IQR)).
FIGURE 1 Participating countries in
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FIGURE 2 a) Inclusion criteria and b) criteria for pre-selection of patients in the different registries. ERS:
European Respiratory Society; ATS: American Thoracic Society; GINA: Global Initiative for Asthma.
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Analysis
A descriptive comparison was performed for the clinical characteristics in the different registries. To
describe differences in treatment regimens and biomarkers, comparisons were made prior to starting
high-cost therapies. For those patients who had already discontinued these therapies, and where
information before start was not available, data from >6 months after stopping high-cost therapies were
used. High-cost therapies were defined as treatments with biologicals, bronchial thermoplasty or
high-altitude treatment.
Results
Data from a total of 3236 patients classified as having severe asthma by the 11 different European
registries were used for the analysis. The registries varied in size (n=27 in Sweden to n=765 in the UK).
The characteristics of the different populations are shown in table 1 (see supplementary material for
further details). None of the participating registries collected the full set of variables requested. Data that
were not collected or not available in a registry are indicated in the various tables.
Differences in baseline clinical characteristics
The mean age of patients ranged from 44.4 (Germany) to 58.3 years (Hungary). The percentage of males
ranged from 30.0% (Slovenia) to 51.9% (Sweden). Current smokers ranged from 0% (Poland and Sweden)
to 9.5% (Belgium). The percentage of ex-smokers ranged from 10.8% (Hungary) to 41.3% (the
Netherlands); in Hungary, only patients with a smoking history <5 pack-years were enrolled into the
registry. Over half of the registries predominantly included patients with adult-onset severe asthma (the
Netherlands, the UK, Hungary, Sweden, Denmark and Slovenia), while four registries consisted mainly of
patients with childhood-onset asthma (Belgium, Italy, Poland and Germany). Based on mean forced
expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) (% pred), patients in the Dutch registry
had the best lung function, while those in the Hungarian registry had the worst lung function (FEV1
76.9% versus 56.0% and FVC 98.3% versus 76.6%). Median blood eosinophil levels ranged from 0.230×109
(the Netherlands) to 0.800×109 cells·L−1 (Sweden), median serum total IgE ranged from 144 (the
Netherlands) to 275 IU·mL−1 (Sweden) and median exhaled nitric oxide fraction (FENO) ranged from 25
(Belgium) to 66 ppb (Slovenia). Between 54.6% (Italy) and 100% (Hungary and Sweden) of the patients
were uncontrolled as judged from patient-reported questionnaire scores (Asthma Control Questionnaire or
Asthma Control Test).
Most registries enrolled patients being treated in a tertiary care centre; however, a small group of patients
was included in primary care (Spain) and four registries (Spain, the Netherlands, Belgium and Hungary)
included up to 33.8% in secondary care hospitals. In most registries >90% of the patients were treated
according to GINA step 4 or 5 guidelines [7]; in Denmark this was 77.6% (evaluated before patients
started biologicals) and in six registries (Hungary, Poland, Sweden, Germany, Italy and Slovenia) 100% of
patients were at GINA step 4 or 5. The percentage of patients on biologicals ranged from 0% (Sweden) to
71.0% (Poland). The most frequently given biological in seven registries was anti-IgE (Belgium, Spain,
Hungary, Poland, Germany, Italy and Slovenia) and in three registries it was anti-IL-5 (the Netherlands,
the UK and Denmark). The registries in the Netherlands, Belgium and Slovenia enrolled patients who had
undergone bronchial thermoplasty, and the registry in the Netherlands also included patients who had
received high-altitude treatment (14%). The mean±SD ICS dose (fluticasone equivalent) ranged from
491±163 (Slovenia) to 1225±445 µg·day−1 (Spain). The maintenance OCS median dose ranged from 7.5
(Hungary) to 10.7 mg·day−1 (Italy).
Treatment regimens of patients starting high-cost therapies
Table 2 shows medication data of 1960 patients included in the registries prior to starting or >6 months
after stopping high-cost therapies. In six registries (Belgium, Spain, Hungary, Sweden, Slovenia and
Denmark), most patients were not treated according to GINA step 5 treatment. Short-acting β-agonists
(SABAs) were the most used reliever medications in all but one registry (Spain) where the most frequent
relievers were short-acting muscarinic antagonists (SAMAs). SABA and/or SAMA use ranged from 4.0%
(Italy) to 100% (Hungary, Poland and Sweden). LABA use ranged from 80.3% (Poland) to 100% (Italy,
Hungary and Sweden). Long-acting muscarinic antagonists (LAMAs) were used in all countries and
ranged from 14.0% (Hungary) to 56.4% (the UK). In seven registries (Spain, Hungary, Poland, Sweden,
Italy, Slovenia and the UK) all patients were on ICS, while in the Netherlands, Belgium and Denmark this
was 99.3%, 97.4% and 93.9%, respectively. Mean±SD fluticasone equivalent doses ranged from 1320±465
(Spain) to 570±497 µg·day−1 (Italy).
Figures 3 and 4 provide an overview of maintenance therapy for severe asthma patients before starting
with anti-IL-5 biologicals (mepolizumab, reslizumab or benralizumab; n=617) and anti-IgE biologicals
(omalizumab; n=514) (see supplementary material for further details). In most of the registries, all patients
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TABLE 1 Baseline characteristics of patients included in different severe asthma registries that are part of SHARP
UK Belgium Italy Spain Netherlands Germany Poland Slovenia Hungary Denmark Sweden
Patients 765 629 437 410 237 209 193 140 130 59 27
Age years 47.6±14.5 56.9±14.7 54.1±13.7 56.4±14.8 52.8±14.2 44.4±20.4 48.4±14.6 53.5±12.8 58.3±12.9 51.9±16.1 50.0±8.6
Male 285 (37.3) 265 (42.1) 183 (41.9) 133 (32.4) 112 (47.3) 98 (46.9) 76 (39.4) 42 (30.0) 42 (32.3) 28 (47.5) 14 (51.9)
Smoking status
Current smoker 30 (4.1) 60 (9.5) 12 (2.7) 29 (7.1) 2 (0.9) 5 (2.4) 0 (0) 1 (0.7) 8 (6.2) 2 (4.0) 0 (0)
Never-smoker 526 (71.7) 368 (58.5) 352 (80.5) 281 (68.5) 136 (57.9) 125 (59.8) 171 (88.6) 92 (65.7) 108 (83.1) 24 (48.0) 16 (59.3)
Ex-smoker 178 (24.3) 201 (32.0) 73 (16.7) 100 (24.4) 97 (41.3) 79 (37.8) 22 (11.4) 47 (33.5) 14 (10.8) 19 (38.0) 11 (40.7)
Pack-years 15 (5–20) 15 (6–27) 9 (4–15) 19 (10–23) 10 (4–19) 8 (2–15) 12.5 (15) 10 (3–20) <5 8.5 (2.2–15) 5 (4–9)
BMI kg·m−2 30.6±7.4 27.7±12.6 26.2±5.0 28.2±6.0 28.3±5.4 27.4±10.8 28.1 27.1±5.8 26.9±5.4 27.1±5.4 27.7±5.3
FEV1 % pred 67.8±22.8 67.9±21.6 71.4±20.2 68.1±36.1 76.9±22.2 70.3±23.0 63.2±23.5 69.6±19.8 56.0±16.8 72.0±19.1 66.0±19.9





























































FENO ppb 41 (23–77) 25 (14–42) 32 (17–64) 33 (19–52) 33 (20–60) 33 (19–79) 27 (27) 66 (27–101) 32 (18–56) 26 (13–49) 57 (29–80)
Adult-onset asthma 385 (59.8) 200 (31.8) 105 (24.0) NA 129 (63.2) 61 (39.4) 68 (35.2) 110 (78.6) 89 (68.5) 26 (78.8) 24 (88.9)
ACQ 3.0±1.3 2.5±1.3 2.9±1.5 NA 2.1±1.2 2.6±1.5 3.3±0.9 NA NA 2.4±1.4 1.8±1
ACT NA 13.2±5.4 17.2±5.4 15.9±5.8 NA 15±6.0 12.3 16.7±5.5 16.6±1.2 NA 12±3.8
Uncontrolled based
on ACQ/ACT
581 (84.6) 331 (76.1) 250 (54.6) 221 (68.8) 88 (61.5) 135 (71.1) 191 (98.9) 87 (64.0) 130 (100) 21 (63.6) 27 (100)
Hospitalisation in
last year
291 (39.5) 229 (36.4) 53 (17.6) 52 (12.7) NA 55 (32.4) 78 (40.4) 61 (43.6) 36 (27.7) 16 (48.5) 1 (3.7)
Included in:
Primary care 0 (0) 0 (0) 0 (0) 16 (3.9) 0 (0) NA 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Secondary care 0 (0) 52 (8.3) 0 (0) 125 (30.5) 76 (32.1) NA 0 (0) 0 (0) 44 (33.8) 0 (0) 0 (0)
Tertiary care 765 (100) 577 (91.7) 437 (100) 269 (65.6) 161 (67.9) NA 193 (100) 139 (100) 86 (66.2) 59 (100) 27 (100)
GINA step 4
treatment
162 (21.2) 309 (49.0) 18 (5.7) 197 (48.1) 113 (47.7) 130 (62.2) 53 (27.5) 87 (62.6) 93 (71.5) 24 (49.0) 15 (55.6)
GINA step 5
treatment
569 (74.4) 320 (51.0) 297 (94.3) 210 (51.2) 118 (49.8) 79 (37.8) 140 (72.5) 52 (37.4) 37 (28.5) 14 (28.6) 12 (44.4)
Biological use
Total 479 (64.5) 160 (25.0) 215 (49.2) 210 (51.2) 82 (34.6) 80 (38.3) 137 (71.0) 66 (47.5) 30 (23.1) 59 (100) 0 (0)
Anti-IgE 115 (25.4) 130 (21.0) 180 (41.2) 197 (48.1) 29 (12.2) 41 (19.6) 129 (66.8) 59 (42.4) 16 (12.3) 18 (30.5) 0 (0)
Anti-IL-5 337 (74.4) 30 (5.0) 35 (8.0) 13 (3.2) 53 (22.4) 39 (18.7) 8 (4.1) 7 (5.0) 14 (10.8) 41 (69.5) 0 (0)
Anti-IL-4/IL-13 1 (0.2) 0 (0) NA 0 (0) 0 (0) NA 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Thermoplasty 0 (0) 9 (1.4) NA 0 (0) 3 (1.3) NA 0 (0) 2 (1.4) 0 (0) 0 (0) 0 (0)
High-altitude
treatment
NA 0 (0) NA 0 (0) 33 (14) NA 0 (0) 0 (0) 0 (0) NA 0 (0)























Data are presented as n, mean±SD, n (%) or median (interquartile range). Discrepancies between n (%) and total number of patients are due to missing data. BMI: body mass index; FEV1:
forced expiratory volume in 1 s; FVC: forced vital capacity; FENO: exhaled nitric oxide fraction; ACQ: Asthma Control Questionnaire; ACT: Asthma Control Test; GINA: Global Initiative for




















TABLE 2 Medication prior to starting (or >6 months after stopping) high-cost therapy (biologicals, bronchial thermoplasty and high-altitude treatment)
UK Belgium Italy Spain Poland Netherlands Hungary Slovenia Denmark Sweden Germany
Patients 477 469 219 210 193 143 100 73 49 27 NA
GINA step 4 152 (31.9) 347 (74.0) 2 (2.0) 166 (79.0) 53 (27.5) 54 (37.8) 74 (74.0) 42 (57.5)) 24 (49.0) 15 (55.6) NA
GINA step 5 325 (68.1) 109 (23.2) 98 (98.0) 44 (20.9) 140 (72.5) 87 (60.8) 26 (26.0) 31 (42.5) 14 (28.6) 12 (44.4) NA
SABA 444 (93.3) 377 (90.2) 4 (4.0) 32 (15.2) 193 (100) 107 (74.8) 100 (100) 43 (58.9) 29 (59.2) 27 (100) NA
SAMA NA NA NA 175 (83.3) 38 (19.7) 25 (17.5) 0 (0) 28 (38.3) 1 (2.0) 8 (29.6) NA
LABA 436 (92.2) 457 (97.4) 219 (100) 206 (98.1) 155 (80.3) 135 (94.4) 100 (100) 72 (98.6) 43 (87.8) 27 (100) NA
LAMA 269 (56.4) 113 (24.1) 40 (40.4) 35 (28.9) 37 (19.2) 42 (29.4) 14 (14.0) 54 (74.0) 22 (44.9) 8 (29.6) NA
ICS 477 (100) 457 (97.4) 219 (100) 212 (100) 193 (100) 142 (99.3) 100 (100) 73 (100) 46 (93.9) 27 (100) NA
ICS dose# µg·day−1 973±508 986±479 570±497 1320±465 1220±668 1178±797 909±386 700.1±207.4 1073±372 1196±641 NA
LTRA 188 (39.4) 251 (53.5) 37 (37.4) 123 (58.6) 128 (66.3) 29 (20.3) 45 (45.0) 30 (41.1) 28 (57.1) 21 (77.8) NA
Theophylline 120 (25.2) 65 (13.9) 7 (7.1) 22 (11.2) 52 (26.9) 6 (4.2) 35 (35.0) 1 (1.4) 5 (10.2) 2 (7.4) NA
OCS maintenance 325 (68.1) 102 (21.7) 105 (71.9) 45 (21.4) 87 (45.1) 88 (60.8) 26 (26.0) 31 (42.5) NA 17 (63.0) NA
OCS dose mg·day−1
¶
Defined daily dose¶ NA NA NA 1.81±0.89 NA 1.4±1.1 0.67±0.34 NA NA 0.94±0.29 NA
Median (IQR) 10.0 (10.0–20.0) 10.0 (5.0–10.0) 10.0 (5.0–10.0) 10.0 (5.0–10.0) 7.0 (7.0–15.0) 10.0 (7.5–19.4) 6.9 (3.4–10.0) 10.0 (5.0–12.0) NA 10.0 (7.5–10.0) NA
NSAID NA 25 (5.0) NA NA 44 (22.8) 3 (2.2) 0 (0) NA NA 20 (74.1) NA
Data are presented as n, n (%) or mean±SD, unless otherwise stated. Discrepancies between n (%) and total number of patients are due to missing data. GINA: Global Initiative for
asthma; SABA: short-acting β-agonist; SAMA: short-acting muscarinic antagonist; LABA: long-acting β-agonist; LAMA: long-acting muscarinic antagonist; ICS: inhaled corticosteroid;
LTRA: leukotriene receptor antagonist; OCS: oral corticosteroid; IQR: interquartile range; NSAID: nonsteroidal anti-inflammatory drug; NA: not available. #: dose expressed as fluticasone
equivalent; ¶: dose expressed as prednisone equivalent.
TABLE 3 Biomarker data from patients before starting with biological therapies (anti-interleukin (IL)-5 and anti-IgE)


























129 (44–404) 270 (90–376) 431 (168–594) 405 (360–791) 140 (48–366) 56 (29–200) 149 (53–256) 164 (58–342) 275 (115–820) NA NA






















324 (139–567) 238 (107–626) 243 (114–515) 154 (74–388) NA 172 (118–233) 118 (32–795) 148 (92–228) NA NA NA
FENO ppb 39 (24–82) 29 (16–41) 36 (20–57) NA NA 34 (27–80) 75 (41–92) 10 (12–30) NA NA NA




















were on ICS before starting anti-IL-5 (in Denmark this was only 94.7%), although there were differences
in ICS dose, ranging from 1335±529 (Poland) to 700±118 µg·day−1 (Slovenia). Information on treatment
before starting omalizumab was available in six registries. ICS use was <100% in Belgium (96.6%) and
Denmark (90.9%), and the mean±SD dose ranged from 1344±540 (Spain) to 772±191 µg·day−1 (Slovenia).
In four registries, all patients were using LABA before starting anti-IL-5 (Spain, Hungary, Sweden and
Slovenia), while in other countries this ranged from 25.0% (Poland) to 94.4% (the Netherlands). LAMA
use in patients starting anti-IL-5 ranged from 0% (Hungary) to 79.1% (Slovenia). LAMA use in patients
starting anti-IgE starting ranged from 12.5% (Hungary) to 100% (Slovenia). OCS was used as a
maintenance therapy before starting with anti-IL-5 in all registries and ranged from 21.0% (Belgium) to
63.0% (Sweden) of the population. Before starting anti-IgE, OCS was also used in all registries, ranging
from 9.1% (Denmark) to 56.1% (the UK) of the population.
Table 3 shows differences between registries in biomarkers before starting treatment with biologicals. The
median blood eosinophil levels before starting anti-IL-5 therapy were higher than levels seen before starting
anti-IgE treatment in all registries. The median blood eosinophil levels before starting anti-IL-5 treatment
ranged from 0.270×109 (Denmark) to 0.800×109 cells·L−1 (Sweden). The median serum total IgE
concentrations before starting with anti-IgE treatment ranged from 118 (Slovenia) to 324 IU·mL−1 (the UK).
Discussion
This first collaborative study in the SHARP CRC has made several important observations. Across Europe
there are large differences in characteristics and lifestyle factors of patients with severe asthma. Treatment
regimens and biomarkers in patients starting biologicals and criteria for their prescription also seem to







































































UK ES NL SL PL HU SE BE DM
NA
FIGURE 3 a) Overview of maintenance treatment of patients that start with anti-interleukin (IL)-5 biologicals.
NL: Netherlands; BE: Belgium; ES: Spain; HU: Hungary; PL: Poland: SE: Sweden; SL: Slovenia; DM:
Denmark; ICS: inhaled corticosteroid; LABA: long-acting β-agonist; LAMA: long-acting muscarinic antagonist;
OCS: oral corticosteroid; NA: not available. b) Mean±SD ICS dose (fluticasone equivalent) in patients that start
with anti-IL-5 biological therapies. c) Median (interquartile range) maintenance OCS dose (prednisone
equivalent) in patients that start with anti-IL-5 biological therapies. Median values: UK 10 mg·day−1, Spain
12.5 mg·day−1, Netherlands 10 mg·day−1, Slovenia 10 mg·day−1, Poland 9 mg·day−1, Hungary 10 mg·day−1,
Sweden 10 mg·day−1 and Belgium 2.5 mg·day−1.
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biological therapies, who we would consider to suffer from severe asthma, did not fit the criteria of the
definition of severe asthma as defined by ERS/ATS and GINA, and they also did not meet the criteria used
to recruit patients in the phase 3 trials of these biological therapies. The reasons for these differences are
as yet unclear and will need to be addressed as the SHARP CRC moves to harmonise the data that are
collected in the different national registries.
Differences between registries
The data in this study clearly show large variation in the baseline characteristics of asthmatic subjects
enrolled in the 11 European registries. This could be due to differences in the definition of severe asthma
across the different registries. The disparities could, in principle, also reflect differences in overall severity
of the broader asthma population in each country; however, our data do not allow us to explore to what
extent the enrolled patients reflect the general asthma population. Lung function results, expressed as
pre-bronchodilator FEV1 and FVC (% pred), were in both cases highest in the Netherlands and lowest in
Hungary, with differences as high as 20.9% and 21.7%, respectively. We do not presently know what
causes these differences; patients in the two registries were on similar treatment, and FENO levels and blood
eosinophil counts were not different. However, possible explanations may be in differences in lifetime dose
or onset of therapy with ICS, which would result in progressive loss of lung function, or in the difference
in OCS use between Hungary and the Netherlands (60% versus 26% before high-cost therapies) and the
resulting effects on blood eosinophils and FENO. Important differences were also found in the percentage
of adult-onset asthma patients (64.9%), a clinical phenotype of asthma that is known to be more severe
than early-onset asthma [8]. Furthermore, the percentages of patients with uncontrolled asthma based on
questionnaire scores (45.4% difference) and asthma-related hospitalisation during the past 12 months
(43.5% difference) point to possible differences in the quality of care (e.g. access to specialist care). Other
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FIGURE 4 a) Overview of maintenance treatment of patients that start with anti-IgE biologicals. BE: Belgium;
ES: Spain; HU: Hungary; PL: Poland: SL: Slovenia; DM: Denmark; ICS: inhaled corticosteroid; LABA:
long-acting β-agonist; LAMA: long-acting muscarinic antagonist; OCS: oral corticosteroid; NA: not available.
b) Mean±SD ICS dose (fluticasone equivalent) in patients that start with anti-IgE biological therapies. c) Median
(interquartile range) maintenance OCS dose (prednisone equivalent) in patients that start with anti-IgE
biological therapies. Median values: UK 13 mg·day−1, Spain 10.7 mg·day−1, Belgium 9 mg·day−1, Poland
7 mg·day−1 and Hungary 5 mg·day−1.
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(including cigarette smoke) that may have resulted in worsening lung function. While these factors could
not be assessed in the current analysis because relevant data were not collected, they could be the subject
of future studies by the SHARP CRC.
Smoking patients or smokers with a history ⩾10 pack-years are almost never included in asthma trials due
to the risk of confounding effects of smoking and the undesired inclusion of chronic obstructive
pulmonary disease patients. In real-life, however, significant proportions of severe asthma patients also
smoke, with rates >4% found in Belgium, the UK, Spain and Hungary. Again, differences between
registries from different countries were large, up to 30.7 percentage points for the percentage of
never-smokers, with differences in median pack-years >14 years. Interestingly, differences in smoking do
not necessarily reflect the differences in lung function; the Netherlands included more ex-smokers and
median pack-years is higher than in Hungary despite patients in Hungary having worse lung functions. In
general, BMI appeared to be less variable. Nevertheless, the largest difference here was 4.4 kg·m−2, and the
difference in mean BMI between the UK (30.6 kg·m−2) and Italy (26.2 kg·m−2) suggests that obesity in
severe asthma patients may be a significant problem in the UK, but not in Italy.
Treatment of patients starting on high-cost therapies
The differences in OCS use before starting high-cost therapies between registries from different countries
were striking. The percentage of patients on maintenance OCS varied greatly (largest difference 50.5
percentage points between Italy and Spain), suggesting very different prescribing regimens across Europe.
When specifically studying patients starting anti-IL-5 and omalizumab, large differences in treatment
regimens were also found. OCS use in those starting anti-IL-5 treatment was highest in the UK and
differed most from clinical practice in Belgium (52.2% difference). As expected, all patients starting
anti-IL-5 biologicals were using regular ICS, although there was marked variation in the daily dose, with
fluticasone equivalent differences of up to 635 µg·day−1 (Poland versus Slovenia). Why this is the case is
unclear. Potential explanations, which will require focused study by the SHARP CRC, include cost of
treatment and fear of high-dose treatment-related side-effects.
Patients starting omalizumab showed similar differences between registries, with largest differences in OCS
use and mean dose between the UK and Belgium (45.1 percentage points and 10.0 mg·day−1, respectively).
All patients starting omalizumab were on ICS except for in Belgium and the largest fluticasone equivalent
difference was 571 µg·day−1 (Spain versus Slovenia). LAMA can be used as step-up treatment after GINA
step 4 [9], and the results show that the percentage of patients on LAMA in both anti-IL-5 and anti-IgE
therapies varied significantly. LAMA use was common in Slovenia, although this observation was based on
a small sample size (24 patients starting anti-IL-5 antibody and nine patients starting omalizumab). Of
note, LAMAs were hardly used in Hungary, Poland and Spain. Taken together, these differences in
treatment suggest a difference in criteria applied (not necessarily required) to prescribe anti-IL-5 and
anti-IgE biologicals.
Deviations from guidelines and trial criteria
An important issue that this study highlights is that criteria on which severe asthma is defined currently
by international guidelines and those used in clinical trials with biologicals do not match clinical reality.
For example, not all patients enrolled in the registries are on GINA step 4/5 treatment and ICS doses in
patients starting with biologicals do not always correspond to those applied as inclusion criteria in trials
and in the joint ERS/ATS criteria. Fluticasone equivalence of >1000 μg·day−1 (ex-actuator: 880 μg·day−1)
was an inclusion criterion for mepolizumab trials [10, 11] and doses >1000 μg·day−1 are considered high
dose according to the ERS/ATS guidelines [3]. In this study, patients in several registries (Belgium, the UK,
Spain, Hungary and Slovenia) were on mean doses <1000 μg·day−1, suggesting that a significant
proportion of patients in the registries would not meet the mepolizumab trial inclusion criteria or do not
meet the international ERS/ATS criteria for severe asthma. This deviation in ICS dose can be potentially
explained by different interpretations between what is considered high-dose ICS by the ERS/ATS and
GINA (>500 µg·day−1 fluticasone equivalent). Additionally, for the Belgian registry, these data can be
partially explained by the inclusion of a large number (∼25–30%) of non-type 2 asthma patients, who may
be less responsive to ICS. A similar picture arises with anti-IgE treatment. Mean fluticasone equivalent ICS
doses before starting omalizumab were <1000 μg·day−1 in Belgium, the UK and Slovenia; thus, at least part
of the population does not have severe asthma according to international ERS/ATS guidelines.
The first clear message that arises is the need for agreement between ERS/ATS guidelines and GINA, as
the current differences in definitions are a cause for confusion among pulmonary physicians. One of the
possible explanations of the differences between the characteristics of patients included in the severe
asthma registries and the characteristics that were expected according to the ERS/ATS guidelines definition
of severe asthma might suggest that some patients do not fulfil guideline criteria but are being considered
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as having severe asthma by clinical severe asthma experts. These differences will require more analysis,
including the processes whereby biologicals are offered to patients. In the UK, the main criteria required
by the National Institute of Clinical Excellence for both omalizumab and anti-IL-5 biologicals are the
frequency of exacerbations (three or four exacerbations) in the previous 12 months or maintenance OCS
[12–14], and these are implemented rigorously by the commissioning groups that regulate the use of
biologicals. One plausible explanation for the observation in the UK is that the frequency of exacerbations
is not used to define asthma severity. Furthermore, patients treated with biologicals in clinical practice do
not always fulfil the criteria that were used for inclusion in the biological trials. Although this study was
not designed to evaluate the efficacy of biological therapies, this suggests a need for observational studies
targeting the efficacy of biologicals in patients who were not enrolled in trials that resulted in their
approval. Such observational studies would provide more insight into the efficacy of biologicals in daily
practice; however, the differences in countries as described here should be considered.
European harmonisation
The aforementioned issues raise awareness that severe asthma research needs to consider more the
complexity and heterogeneity between different populations of chronic respiratory diseases. New discoveries
will need large amounts of data that can only be collected in international consortia and therefore there is an
urgent need to harmonise datasets on severe asthma across Europe. An international consensus needs to be
reached on a minimal set of variables that should be collected in the national registries that take part in
SHARP. When studying lung function, for example, all registries currently include information on
pre-bronchodilator FEV1, but only nine out of 11 registries also record pre-bronchodilator FVC. Information
on lung function reversibility is even less common, with post-bronchodilator FEV1 currently recorded in
only seven registries. The bigger challenge, however, lies in the harmonisation of definitions of variables. The
definitions for FEV1 and FVC are rather simple, whereas the definition for adherence to therapy is not
straightforward. Countries retrieved these data in different ways: by checking prescription records, check-up
by a dedicated asthma nurse, doctor’s assessment or checking a database whether a patient was registered as
showing “good compliance”. Accordance on a minimal set of well-defined key variables is needed to increase
the usability of the SHARP platform and should be the subject of future studies. The data collected in the
current study should be a stepping-stone to start the discussion about more standardised practice for severe
asthma care in Europe.
Earlier research
Several of the participating registries have already published analyses of their data [15–17]. The
heterogeneity found in the current study is in line with the analyses of registries in Belgium, Italy and the
UK, where differences in inflammatory characteristics [15] among patient populations were found even
between centres in the same country [16] and differences in phenotype were identified [17]. Analyses of
other international cohorts also show a marked heterogeneity across severe asthma patients. The
pan-European U-BIOPRED (Unbiased BIOmarkers for the Prediction of REspiratory Disease outcomes)
cohort has provided evidence for the existence of different phenotypes and endotypes of severe asthma as
well as evidence for “cluster-migrating” patients [18]. The US SARP (Severe Asthma Research Program)
cohort has also shown that heterogeneity exists even within clinical clusters [19]. Our present study further
confirms that the severe asthma phenotype may be an oversimplification of the clinical reality and that
different phenotypes with different therapeutic needs exist within the population of severe asthma patients
currently viewed as a single group. Large differences in prevalence of severe asthma that have been
described [20] support the idea that current guidelines may be ambiguous.
Strengths/limitations
This first ever attempt to integrate registry data across Europe has limitations. With over 3000 patients
included in the analysis, it is one of the largest comparisons of this population to date, providing insight
into the characteristics and treatments of this heterogeneous group across Europe. With representation
from Southern, Western, Eastern and Northern Europe there is a good geographical distribution; thus,
the influence of differences in environmental and genetic factors and in healthcare systems have been
incorporated, but to what extent these influence the observed heterogeneity is unclear. Perhaps the
biggest, but inevitable, weakness is the retrospective nature of the study. Indeed, there was significant
variation in inclusion criteria and only half the registries used the joint ERS/ATS definition of severe
asthma. Furthermore, not all patients were treated in a specialised asthma centre, while half the registries
solely included patients in tertiary care, reflecting diversity in what clinicians in different European
countries consider to be severe asthma. A further important limitation of the current data is
pre-selection of specific patient subgroups; in particular, the registries in the Netherlands, Sweden and
Slovenia focused on including patients that were starting biological therapies, which is expected to result
in cohorts composed of the most severe patients. However, we expected this pre-selection of more severe
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patients to be reflected in a selection of patients who met the current international guidelines, but that
was not the case. Some registries, i.e. Sweden, are currently run in only one city or even one hospital,
which implies that data do not necessarily reflect a country, but sometimes a specific situation in a
country.
Conclusions
In summary, this study shows that the population of severe asthma patients in Europe is heterogeneous
and differs in both clinical characteristics and treatment. These results have several key implications.
First, severe asthma populations and treatment, even when users of biologicals are excluded, greatly
differ between countries. Thus, results from single-centre trials, or even multicentre trials in the same
country, cannot necessarily be extrapolated to other countries. Second, the definition of severe asthma
in current guidelines does not comply with the characteristics of real-world severe asthma patients and
therefore there might be differences in the application of these guidelines in the different countries.
Third, the first key messages underline the importance of harmonisation of severe asthma databases
across Europe and the need for long-term follow-up of the patient. A consensus on the data that must
be collected to provide solutions to these challenges should be agreed and this will provide a logical
next step for the SHARP CRC. Of importance to future research in the SHARP CRC, the use of
aggregated data proved to be a relatively easy way to obtain data that can be used for international
collaboration.
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